Insmed Incorporated — News

Harmony Biosciences, Acadia, Biogen, Insmed and Agios show positive Earnings ESPs ahead of Q2 results, setting up closely watched earnings reports.

zacks.com - 2026-07-27 13:41:16

BRIDGEWATER, N.J., July 23, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that it will release its second-quarter 2026 financial results on Thursday, August 6, 2026.

prnewswire.com - 2026-07-23 07:00:00

Andra AP fonden lifted its position in shares of Insmed, Inc. (NASDAQ: INSM) by 114.8% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 77,970 shares of the biopharmaceutical company's stock after acquiring an additional 41,670 shares during the

defenseworld.net - 2026-07-22 04:03:17

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

benzinga.com - 2026-07-21 07:58:34

Wall Street analysts are making bold moves on Tuesday, shaking up ratings for some of the biggest names in tech, biotech, and retail in ways that could catch investors off guard. Find out which stocks got slashed and which ones earned surprise upgrades.

247wallst.com - 2026-07-21 07:41:44

Stanley Druckenmiller doesn't do consensus. The Duquesne Family Office's latest 13F reveals a top-five long book that skips the mega-cap tech herd almost entirely: a Mexican discount grocer, two biotech names on wildly different trajectories, the one semiconductor stock nobody can ignore, and an Argentine oil producer sitting on a shale reserve about to unlock its first export pipeline.

247wallst.com - 2026-07-20 11:36:41

Bank of New York Mellon Corp lessened its stake in shares of Insmed, Inc. (NASDAQ: INSM) by 9.2% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,262,749 shares of the biopharmaceutical company's stock after selling 127,293 shares

defenseworld.net - 2026-07-19 04:27:36

Insmed Incorporated (INSM) Discusses 12-Month Results From Ongoing TPIP Open-Label Extension Study in PAH Patients Transcript

seekingalpha.com - 2026-07-16 16:26:35

Insmed Incorporated (NASDAQ:INSM) on Thursday reported 12-month results from the ongoing open-label extension (OLE) study of its once-daily treprostinil palmitil inhalation powder (TPIP) in pulmonary arterial hypertension (PAH) patients.

benzinga.com - 2026-07-16 14:32:08

Insmed NASDAQ: INSM reported 12-month results from an ongoing open-label extension study of TPIP in patients with pulmonary arterial hypertension, saying the data showed sustained efficacy measures and a generally favorable safety profile over longer-term use.

marketbeat.com - 2026-07-16 11:05:22

– 12-Month Data Demonstrated Sustained Improvement with TPIP Across All Secondary Efficacy Measures Including Reduction in Mortality Risk Status by REVEAL Lite 2.0– –Placebo Crossed Group Demonstrated Treatment Response on TPIP, Achieving Similar Outcomes to the TPIP Continued Group by Month 12– –TPIP Was Safe and Well-tolerated with No Newly Identified Safety Signals through Month 12; Doses Up to 1,280 µg Once Daily Were Permitted in the OLE Study– – These OLE Data, Combined with Once-Daily Inhaled Administration, Reinforce TPIP's Potential to Become the Prostanoid of Choice for Patients with PAH – – Insmed to Host Investor Call Thursday, July 16, 2026, at 8:00 a.m. ET – BRIDGEWATER, N.J.

prnewswire.com - 2026-07-16 07:00:00

Carillon Eagle Mid Cap Growth Fund stocks delivered solid results in the second quarter. Top securities in the quarter were Datadog, Marvell, Vertiv, Teradyne and Macom Technology Solutions. Top securities in the quarter were Datadog, Marvell, Vertiv, Teradyne and Macom Technology Solutions.

seekingalpha.com - 2026-07-14 08:53:00

Hannover, Germany, June 25, 2026 (GLOBE NEWSWIRE) -- EMBARC Announces Its Intention to Collaborate with Insmed on Landmark Interventional Study Evaluating Disease Modification Potential of Brensocatib in Bronchiectasis —Long-Term, Open-Label Study to Enroll Approximately 3,000 Patients Across Europe—

globenewswire.com - 2026-06-25 05:05:00

BRIDGEWATER, N.J., June 23, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced the appointment of Samuele Butera as Senior Vice President, General Manager, Global Respiratory, effective today.

prnewswire.com - 2026-06-23 07:00:00

The Nasdaq 100 implemented its June quarterly rebalance, which shifts the tide for “the Qs.” Namely, the Invesco QQQ Trust (QQQ) and its cost-efficient sibling, the Invesco Nasdaq 100 ETF (QQQM).

etftrends.com - 2026-06-22 14:19:15

Insmed is maintained at "Strong Buy" due to robust pipeline progress and expanding commercial execution. INSM's key catalysts include ARIKAYCE's sNDA submission for 1st-line MAC Lung Disease in H2 2026 and ongoing regulatory expansion efforts in Japan. TPIP advances with phase 3 PALM-PAH and PALM-ILD studies, targeting large PAH and PH-ILD markets with potential best-in-class, once-daily dosing.

seekingalpha.com - 2026-06-22 07:30:38

NEW YORK, June 11, 2026 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq: NDAQ) today announced the results of the June 2026 quarterly rebalance of the Nasdaq-100 Index (NDX), which will become effective prior to market open on Monday, June 22, 2026. The following five companies will be added to the Index: Astera Labs, Inc.

globenewswire.com - 2026-06-11 20:00:00

Insmed Incorporated (INSM) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

seekingalpha.com - 2026-06-09 13:22:09

BRIDGEWATER, N.J., June 4, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced the granting of inducement awards to 103 new employees.

prnewswire.com - 2026-06-04 07:00:00

BRIDGEWATER, N.J., May 27, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that management will present at the 2026 Goldman Sachs Annual Global Healthcare Conference in Miami on Tuesday, June 9, 2026, at 10:00 a.m.

prnewswire.com - 2026-05-27 07:00:00

Insmed Incorporated (INSM) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript

seekingalpha.com - 2026-05-20 12:50:56

Insmed NASDAQ: INSM Chair and CEO Will Lewis said the company remains confident in the launch trajectory of BRINSUPRI, despite investor concerns over discontinuation rates that followed the company's latest update. Speaking at a Bank of America healthcare conference, Lewis said the company intended to provide “anchor points” around what he described as “one of the strongest launches in recent years.

marketbeat.com - 2026-05-18 03:04:09

Insmed Incorporated (INSM) Presents at Bank of America Global Healthcare Conference 2026 Transcript

seekingalpha.com - 2026-05-12 19:20:46

INSM stock plunges 23% after Q1 sales miss estimates despite 230% revenue growth and strong Brinsupri uptake.

zacks.com - 2026-05-08 11:06:26

Insmed Incorporated (INSM) Q1 2026 Earnings Call Transcript

seekingalpha.com - 2026-05-07 14:51:18

Insmed stock tanked Thursday after its new lung drug, Brinsupri, missed elevated buy-side expectations, though beat sell-side views.

investors.com - 2026-05-07 11:03:53

Insmed (INSM) came out with a quarterly loss of $0.76 per share versus the Zacks Consensus Estimate of a loss of $0.9. This compares to a loss of $1.42 per share a year ago.

zacks.com - 2026-05-07 09:56:02

— Total Company Revenues of $306.0 Million for the First Quarter of 2026— —BRINSUPRI ® (brensocatib) Revenues of $207.9 Million for the First Quarter of 2026, Reflecting 44% Growth Over the Fourth Quarter of 2025— — ARIKAYCE ® (amikacin liposome inhalation suspension) Revenues of $98.1 Million for the First Quarter of 2026, Reflecting 6% Growth Over the First Quarter of 2025— —Company Reiterates 2026 BRINSUPRI Revenue Guidance of at Least $1 Billion and 2026 ARIKAYCE Revenue Guidance of $450 Million to $470 Million— — Phase 3b ENCORE Study of ARIKAYCE in Patients with MAC Lung Disease Met Primary and All Multiplicity-Controlled Secondary Culture Conversion Endpoints— —Phase 3 PALM-PAH Study of TPIP in Patients with PAH Initiated in April 2026— BRIDGEWATER, N.J., May 7, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today reported financial results for the first quarter ended March 31, 2026, and provided a business update.

prnewswire.com - 2026-05-07 07:00:00

— Insmed's Educational Initiative, Suspect Bronchiectasis (Suspect BE), Aims to Elevate Recognition and Diagnosis of Bronchiectasis and Encourage Conversations with a Pulmonologist — — Bronchiectasis Symptoms Often Overlap with COPD or Asthma and May Go Unrecognized for Years, Highlighting the Need to Look Deeper at Respiratory Symptoms — — TV Personality, Ty Pennington, Brings Visibility to the Chronic Lung Condition Through His Experience Caring for His Mother, Who is Living with Bronchiectasis — BRIDGEWATER, N.J., May 6, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced a collaboration with Emmy® Award–winning TV host, designer, and carpenter, Ty Pennington, to launch Suspect Bronchiectasis (Suspect BE).

prnewswire.com - 2026-05-06 16:30:00

—New Data in Non-Cystic Fibrosis Bronchiectasis Further Define Impact of BRINSUPRI ® on Respiratory Symptoms— —Findings from a Pharmacokinetic Study Continue to Support Further Evaluation of Treprostinil Palmitil Inhalation Powder Phase 3 Development Program— —Additionally, Insmed Provides Independent Research Grant to the American Thoracic Society for a Landmark Quality Initiative to Improve Diagnosis of Bronchiectasis across the U.S.— BRIDGEWATER, N.J., May 4, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that it will present six abstracts from across its respiratory portfolio and pipeline at the American Thoracic Society International Conference 2026 (ATS 2026), taking place May 17–20 in Orlando, Florida.

prnewswire.com - 2026-05-04 07:00:00

Insmed (INSM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

zacks.com - 2026-04-30 11:06:07

BRIDGEWATER, N.J., April 30, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that management will present at the following investor conferences: BofA Securities 2026 Healthcare Conference in Las Vegas on Tuesday, May 12, 2026, at 1:40 p.m.

prnewswire.com - 2026-04-30 07:00:00